PRQR - ProQR Therapeutics N.V.
18.60 +0.11 (0.59%)
After hours: 4:00PM EDT
| Previous Close | 18.00 |
| Open | 17.61 |
| Bid | 1.00 x 900 |
| Ask | 23.05 x 1100 |
| Day's Range | 17.04 - 19.02 |
| 52 Week Range | 2.75 - 22.85 |
| Volume | 410,411 |
| Avg. Volume | 419,533 |
| Market Cap | 712.736M |
| Beta (3Y Monthly) | 0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.57 |
| Earnings Date | Nov 19, 2018 - Nov 23, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.25 |
- Simply Wall St.•yesterday
Shareholders Should Check The Ownership Structure Of ProQR Therapeutics NV (NASDAQ:PRQR)
The big shareholder groups in ProQR Therapeutics NV (NASDAQ:PRQR) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a Read More...
- GlobeNewswire•16 days ago
ProQR to Present at the Chardan Genetic Medicines Conference
LEIDEN, the Netherlands, Oct. 02, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, ...
- GlobeNewswire•24 days ago
ProQR Announces Presentations at the OTS Annual Meeting
LEIDEN, the Netherlands, Sept. 24, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, ...
- Zacks•last month
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
- Market Realist•last month
ProQR Therapeutics NV Posted 153.7% Returns in the Last Month
ProQR Therapeutics NV (PRQR) stock has risen 153.7% in the past month, from $7.35 on August 10 to $18.65 on September 10. The growth was mainly driven by positive interim results of its Phase ½ clinical trial evaluating investigational RNA-based oligonucleotide QR-110 in Leber congenital amaurosis 10 (or LCA10) indication. The company has stopped enrolling patients in the Phase 1/2 trial and plans to commence the pivotal Phase 2/3 trial for this investigational drug in the first half of 2019.
- GlobeNewswire•last month
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the closing of its previously announced underwritten public offering of 6,612,500 ordinary shares at a price to the public of $15.75 per share. The closing included the full exercise of the underwriters’ option to purchase 862,500 additional ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds from the offering totaled approximately $104.1 million, before deducting underwriting discounts and commissions and offering expenses. Citigroup, Evercore ISI and RBC Capital Markets acted as joint bookrunners for the offering. H.C. Wainwright & Co. and Chardan acted as co-managers for the offering. Kempen & Co acted as the Company’s European financial advisor in relation to this offering.
- Motley Fool•last month
Why ProQR Therapeutics N.V. Is Soaring Again Today
Last week's momentum continues for this clinical-stage biotech.
- Motley Fool•last month
3 Biotech Stocks That Soared This Week: Are They Buys?
Big news lit a fire under these biotech stocks this week. But can their momentum continue?
- GlobeNewswire•last month
ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares
Citigroup, Evercore ISI and RBC Capital Markets are acting as joint bookrunners for the offering. H.C. Wainwright & Co. and Chardan are acting as co-managers for the offering. Kempen & Co is acting as the Company’s European financial advisor in relation to this offering.
- Zacks•last month
ProQR Up More Than 120% on Favorable Eye Disorder Study Data
ProQR Therapeutics (PRQR) presents positive data from a phase I/II study on QR-110, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
- ACCESSWIRE•last month
Today’s Research Reports on Stocks to Watch: ProQR Therapeutics and Sangamo Therapeutics
NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Shares of one stock soared over 120% on positive results from a trial while the other collapsed on its trial results. ProQR was the winner with a gain of over 120% while Sangamo Therapeutics sank nearly 24%. ProQR Therapeutics N.V. shares exploded on Wednesday and closed up 120.75% on high trading volume.
- GlobeNewswire•last month
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
ProQR intends to use the net proceeds from the offering to fund ongoing research and development activities and for working capital and other general corporate purposes. Citigroup, Evercore ISI and RBC Capital Markets are acting as joint bookrunners for the offering.
- Motley Fool•last month
Here's Why ProQR Therapeutics N.V. Is Skyrocketing Today
Shares jump after the company reports favorable clinical news. Here's what investors need to know.
- ACCESSWIRE•last month
Biotech Stocks & Marijuana Stocks Moving Higher on Wednesday
The NK market got its first big break in late August after Roche/Genentech invested nearly $100 million in up front funding with an option for $5 billion specifically into a company looking to also utilize NK cells. GT Biopharma's Chairman and Chief Executive Officer Dr. Raymond Urbanski stated, that this latest event not only provides validation of the NK cell hypothesis but more specifically of the NK cell - engager concept. "GT Biopharma's innovative NK cell-engager platform incorporates IL-15, a potent activator and proliferator of NK cells.
- MarketWatch•last month
ProQR's stock rockets to pace all gainers after upbeat drug trial results
Shares of ProQR Therapeutics NV (prqr) rocketed 66% to a near 3-year high in active morning trade Wednesday, to pace gainers on all the major exchanges, after the company said results from a phase 1/2 trial for the treatment of Leber's congenital amaurosis, a cause for blindness in children, warranted the progression to a phase 2/3 trial. The company said in the trial, QR-110 demonstrated "meaningful improvement" in vision, as early as two months after treatment and was stable by three months.
- Reuters•last month
ProQR soars as childhood blindness drug succeeds in early trial
Shares of ProQR Therapeutics NV surged 70 percent in premarket trading on Tuesday after an interim analysis of an early-stage trial showed that its experimental treatment for a rare form of childhood blindness improved vision. The Dutch drug developer said it would now stop enrollments for the small study and progress to a mid-stage trial, which is expected to start in the first half of 2019. The trial tested ProQR's RNA-based drug, QR-110, in 10 patients with a certain genetic mutation that causes an eye disorder called Leber's congenital amaurosis 10.
- Benzinga•last month
Benzinga Pro's 6 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Twitter Inc (NYSE: TWTR ) and Facebook, Inc. (NASDAQ: ...
- Reuters•last month
ProQR drug for rare childhood blindness succeeds in early trial
Dutch drug developer ProQR Therapeutics NV said on Tuesday its interim analysis showed that an early-stage trial of an experimental treatment for a rare form of childhood blindness was successful in improving vision. Based on what the company called "encouraging" results, ProQR said it would stop enrolling patients in the study and progress to a mid-stage trial, which is expected to start in the first half of 2019. The early trial tested the RNA-based drug, QR-110, in 10 patients with a certain genetic mutation that resulted in an eye disorder called Leber's congenital amaurosis 10.
- GlobeNewswire•last month
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
LCA10 typically leads to childhood blindness and has no available treatment options. In the trial, QR-110 demonstrated rapid and sustained improvement in vision in patients with LCA10, as measured by visual acuity and the mobility course performance, as well as being well-tolerated with no serious adverse events recorded.
- GlobeNewswire•2 months ago
ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th
ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced it will issue data from a planned interim analysis in the ongoing Phase 1/2 clinical trial of QR-110 in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation (the PQ-110-001 trial) at the 18th International Symposium on Retinal Degeneration (RD2018), which is being held on Sept. 3-8, 2018 in Killarney, Ireland.
- Associated Press•2 months ago
ProQR: 2Q Earnings Snapshot
The Leiden, Netherlands-based company said it had a loss of 27 cents per share. ProQR shares have more than doubled since the beginning of the year. The stock has risen 36 percent in the last 12 months. ...
- GlobeNewswire•2 months ago
ProQR Announces Financial Results for the Second Quarter of 2018
LEIDEN, The Netherlands, Aug. 08, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, ...
- GlobeNewswire•3 months ago
ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids
ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the publication of a peer-reviewed manuscript describing the preclinical validation for the use of QR-110 in the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal Molecular Therapy - Nucleic Acids. LCA10 is a severe inherited retinal dystrophy associated with mutations in the CEP290 gene. QR-110 is an RNA-based drug candidate that has the potential to restore sight or slow down the process of vision loss in patients with LCA10 by correcting the most common mutation causing LCA10, p.Cys998X.
